Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Harmony Biosciences Holdings ( (HRMY) ) just unveiled an announcement.
Harmony Biosciences Holdings, a pharmaceutical company, announced strong preliminary net revenues for 2024 and set optimistic revenue guidance for 2025, highlighting its robust pipeline with significant catalysts expected each quarter. The company projects 2025 net revenue between $820 million and $860 million, driven by potential developments in its neuroscience portfolio, including FDA decisions and pivotal trial results, positioning it for long-term growth and stakeholder benefits.
More about Harmony Biosciences Holdings
YTD Price Performance: -2.78%
Average Trading Volume: 740,339
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.93B
For detailed information about HRMY stock, go to TipRanks’ Stock Analysis page.
